139 related articles for article (PubMed ID: 26177294)
1. Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.
William BM; An W; Feng D; Nadeau S; Mohapatra BC; Storck MA; Band V; Band H
Hematology; 2016 May; 21(4):218-24. PubMed ID: 26177294
[TBL] [Abstract][Full Text] [Related]
2. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
[TBL] [Abstract][Full Text] [Related]
3. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.
Naramura M; Nandwani N; Gu H; Band V; Band H
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16274-9. PubMed ID: 20805496
[TBL] [Abstract][Full Text] [Related]
4. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.
Deng L; Li G; Li R; Liu Q; He Q; Zhang J
Cancer Biol Ther; 2010 Jun; 9(11):875-84. PubMed ID: 20364104
[TBL] [Abstract][Full Text] [Related]
5. Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo.
Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Chen J; Li ZY; Zhang RG; Zhu F; Wu G
Mol Cancer Ther; 2015 Jul; 14(7):1582-90. PubMed ID: 25934709
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
[TBL] [Abstract][Full Text] [Related]
7. Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.
An W; Nadeau SA; Mohapatra BC; Feng D; Zutshi N; Storck MD; Arya P; Talmadge JE; Meza JL; Band V; Band H
Oncotarget; 2015 Apr; 6(12):10498-509. PubMed ID: 25871390
[TBL] [Abstract][Full Text] [Related]
8. The Rho kinase inhibitor fasudil augments the number of functional endothelial progenitor cells in ex vivo cultures.
O E; Ahn HY; Kim HK; You JC; Shin JC; Joe YA
Int J Mol Med; 2011 Sep; 28(3):357-63. PubMed ID: 21567077
[TBL] [Abstract][Full Text] [Related]
9. Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis.
Dai K; Wang Y; Tai S; Ni H; Lian H; Yu Y; Liao W; Zheng C; Chen Q; Kuver A; Li J
Cardiovasc Ther; 2018 Dec; 36(6):e12477. PubMed ID: 30380183
[TBL] [Abstract][Full Text] [Related]
10. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice.
Stirzaker RA; Biswas PS; Gupta S; Song L; Bhagat G; Pernis AB
Lupus; 2012 May; 21(6):656-61. PubMed ID: 22345122
[TBL] [Abstract][Full Text] [Related]
11. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Shenkar R; Shi C; Austin C; Moore T; Lightle R; Cao Y; Zhang L; Wu M; Zeineddine HA; Girard R; McDonald DA; Rorrer A; Gallione C; Pytel P; Liao JK; Marchuk DA; Awad IA
Stroke; 2017 Jan; 48(1):187-194. PubMed ID: 27879448
[TBL] [Abstract][Full Text] [Related]
12. Intraradial administration of fasudil inhibits augmented Rho kinase activity to effectively dilate the spastic radial artery during coronary artery bypass grafting surgery.
Takagi T; Okamoto Y; Tomita S; Sato A; Yamaguchi S; Takuwa Y; Watanabe G
J Thorac Cardiovasc Surg; 2011 Aug; 142(2):e59-65. PubMed ID: 21397262
[TBL] [Abstract][Full Text] [Related]
13. Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice.
Wu DJ; Xu JZ; Wu YJ; Jean-Charles L; Xiao B; Gao PJ; Zhu DL
Atherosclerosis; 2009 Nov; 207(1):68-73. PubMed ID: 19473657
[TBL] [Abstract][Full Text] [Related]
14. Exposure to the ROCK inhibitor fasudil promotes gliogenesis of neural stem cells in vitro.
Nizamudeen ZA; Chakrabarti L; Sottile V
Stem Cell Res; 2018 Apr; 28():75-86. PubMed ID: 29448133
[TBL] [Abstract][Full Text] [Related]
15. Fasudil, a Rho‑kinase inhibitor, prevents intima‑media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow‑induced vascular remodeling.
Zhang X; Zhang T; Gao F; Li Q; Shen C; Li Y; Li W; Zhang X
Mol Med Rep; 2015 Nov; 12(5):7317-25. PubMed ID: 26458725
[TBL] [Abstract][Full Text] [Related]
16. RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
Bei Y; Hua-Huy T; Nicco C; Duong-Quy S; Le-Dong NN; Tiev KP; Chéreau C; Batteux F; Dinh-Xuan AT
Exp Lung Res; 2016; 42(1):44-55. PubMed ID: 26873329
[TBL] [Abstract][Full Text] [Related]
17. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Kolavennu V; Zeng L; Peng H; Wang Y; Danesh FR
Diabetes; 2008 Mar; 57(3):714-23. PubMed ID: 18083785
[TBL] [Abstract][Full Text] [Related]
18. Fasudil, an inhibitor of Rho-associated coiled-coil kinase, attenuates hyperoxia-induced pulmonary fibrosis in neonatal rats.
Qi XJ; Ning W; Xu F; Dang HX; Fang F; Li J
Int J Clin Exp Pathol; 2015; 8(10):12140-50. PubMed ID: 26722398
[TBL] [Abstract][Full Text] [Related]
19. Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice.
Ding J; Li QY; Yu JZ; Wang X; Sun CH; Lu CZ; Xiao BG
Mol Cell Neurosci; 2010 Feb; 43(2):201-8. PubMed ID: 19913617
[TBL] [Abstract][Full Text] [Related]
20. Fasudil, an inhibitor of Rho-associated coiled-coil kinase, improves cognitive impairments induced by smoke exposure.
Xueyang D; Zhanqiang M; Chunhua M; Kun H
Oncotarget; 2016 Nov; 7(48):78764-78772. PubMed ID: 27791202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
